Related Experiment Videos

Sirt3 inhibits hepatocellular carcinoma cell growth through reducing Mdm2-mediated p53 degradation

Yuan-Yuan Zhang1, Li-Ming Zhou

  • 1Department of Pharmacology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, Sichuan 610041, PR China.

Biochemical and Biophysical Research Communications
|May 22, 2012
PubMed

Insights

Sirtuin 3 (Sirt3) is downregulated in hepatocellular carcinoma (HCC). Overexpressing Sirt3 inhibits HCC cell growth and promotes apoptosis, suggesting Sirt3 as a potential therapeutic target for liver cancer.

Area of Science:

  • Mitochondrial biology
  • Cancer metabolism
  • Molecular oncology

Background:

  • Sirtuin 3 (Sirt3) is a mitochondrial protein regulating metabolic activity.
  • Sirt3 is implicated in cancer metabolism, but its role in hepatocellular carcinoma (HCC) is unknown.

Purpose of the Study:

  • To investigate the role of Sirt3 in hepatocellular carcinoma (HCC).
  • To determine if Sirt3 can be a therapeutic target for HCC.

Main Methods:

  • Analysis of Sirt3 protein expression in human HCC tissues.
  • Overexpression of Sirt3 in HCC cell lines (HepG2, HuH-7) using adenovirus.
  • Assessment of cell growth, apoptosis (LDH leakage, TUNEL assay, AIF translocation), intracellular NAD(+) levels, and signaling pathways (ERK1/2, Akt, JNK, p53/Mdm2).

Main Results:

  • Sirt3 protein expression was significantly downregulated in HCC tissues.
  • Sirt3 overexpression inhibited HCC cell proliferation and induced apoptosis.
  • Sirt3 modulation affected NAD(+) levels, ERK1/2, Akt, and JNK signaling.
  • Sirt3 overexpression increased p53 levels by inhibiting Mdm2-mediated degradation.

Conclusions:

  • Sirt3 plays a critical role in the development and progression of HCC.
  • Sirt3 acts as a tumor suppressor in HCC.
  • Sirt3 represents a promising therapeutic target for hepatocellular carcinoma.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...